Clinical Trial Update: Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE [Phase 3]

View source ↗

Summary

Phase 3 trial assessing Cu64-DOTATATE imaging in patients with known or suspected somatostatin receptor–positive neuroendocrine tumors has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• [Cu64]DOTATATE (Copper-64 DOTATATE)

Snippet

Sponsor: Radiomedix, Inc. | Conditions: Neuroendocrine Tumors | Phase 3 | Status: COMPLETED | Results posted: 2022-12-22